NRIX Q2 2025 Earnings
Reported Jul 9, 2025 at 4:02 PM ET · SEC Source
Q2 25 EPS
$-0.52
BEAT +30.15%
Est. $-0.74
Q2 25 Revenue
$44.1M
BEAT +151.56%
Est. $17.5M
vs S&P Since Q2 25
+38.5%
BEATING MARKET
NRIX +54.9% vs S&P +16.5%
Market Reaction
Did NRIX Beat Earnings? Q2 2025 Results
Nurix Therapeutics delivered a standout fiscal second quarter, with revenue of $44.06 million beating the $17.51 million consensus by 151.56% and a per-share loss of $0.52 coming in well ahead of the $0.74 estimate, representing a 30.15% positive sur… Read more Nurix Therapeutics delivered a standout fiscal second quarter, with revenue of $44.06 million beating the $17.51 million consensus by 151.56% and a per-share loss of $0.52 coming in well ahead of the $0.74 estimate, representing a 30.15% positive surprise. The headline driver was collaboration activity, specifically $30.00 million in license revenue tied to two Sanofi license extensions, including the exercise of its option on the STAT6 program featuring degrader candidate NX-3911, alongside a $5.00 million clinical milestone from Gilead. Together, those payments helped push total revenue up 264.3% from $12.09 million in the year-ago quarter. Retail investor sentiment turned notably bullish following the report, with shares jumping on the results. Looking ahead, Nurix expects to initiate pivotal trials for lead asset bexobrutideg in relapsed/refractory CLL in the second half of calendar 2025, while a cash position of $485.80 million provides a firm financial foundation to advance its broader pipeline across oncology and autoimmune indications.
Key Takeaways
- • $30 million in license revenue from two Sanofi license extensions during the quarter
- • $5 million clinical milestone achieved under Gilead collaboration
- • Accelerated enrollment and pivotal trial preparation for bexobrutideg driving increased R&D spending
NRIX YoY Financials
Q2 2025 vs Q2 2024, source: SEC Filings
NRIX Revenue by Segment
With YoY comparisons, source: SEC Filings
“During our second quarter, Nurix delivered important collaboration milestones, resulting in Sanofi's extension of its license for our STAT6 program and FDA clearance of the IND for IRAK4 degrader GS-6791/NX-0479 in collaboration with Gilead.”
— Arthur T. Sands, Q2 2025 Earnings Press Release
NRIX Earnings Trends
NRIX vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
NRIX EPS Trend
Earnings per share: estimate vs actual
NRIX Revenue Trend
Quarterly revenue: estimate vs actual
NRIX Quarterly Results
4 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 MISS | $-0.76 | $-0.79 | -3.32% | $6.3M | -56.09% |
| Q4 25 BEAT FY | $-0.92 | $-0.82 | +10.85% | $13.6M | +1.22% |
| FY Full Year | — | $-3.05 | — | $84.0M | — |
| Q3 25 MISS | $-0.85 | $-1.03 | -21.08% | $7.9M | -50.85% |
| Q2 25 BEAT | $-0.74 | $-0.52 | +30.15% | $44.1M | +151.56% |